Jackson Square Partners LLC Sells 231 Shares of Eli Lilly and Company (NYSE:LLY)

Jackson Square Partners LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 4.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,521 shares of the company’s stock after selling 231 shares during the quarter. Jackson Square Partners LLC’s holdings in Eli Lilly and Company were worth $3,490,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in LLY. Principal Financial Group Inc. raised its position in shares of Eli Lilly and Company by 5.3% during the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after buying an additional 60,306 shares during the last quarter. Penserra Capital Management LLC raised its holdings in Eli Lilly and Company by 45.2% in the 3rd quarter. Penserra Capital Management LLC now owns 870 shares of the company’s stock valued at $770,000 after acquiring an additional 271 shares in the last quarter. Alpha DNA Investment Management LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $285,000. Cahill Financial Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 11.8% during the 3rd quarter. Cahill Financial Advisors Inc. now owns 247 shares of the company’s stock worth $219,000 after purchasing an additional 26 shares in the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of Eli Lilly and Company by 3.5% in the third quarter. Fisher Asset Management LLC now owns 5,058,101 shares of the company’s stock valued at $4,481,175,000 after purchasing an additional 169,391 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 3.4 %

Shares of LLY opened at $865.94 on Tuesday. The business’s fifty day moving average price is $837.36 and its two-hundred day moving average price is $837.97. The firm has a market capitalization of $821.06 billion, a price-to-earnings ratio of 73.95, a PEG ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $711.40 and a 52 week high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company announced that its board has approved a share repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on LLY shares. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Bank of America reiterated a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Citigroup cut their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a report on Friday, January 17th. Finally, Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a report on Thursday, January 16th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.